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Altered temporal sensitivity 
in obesity is linked to pro-
inflammatory state
federica Scarpina  1*, paolo Marzullo1,2, Stefania Mai1, Alessandro Mauro1,3, 
Massimo Scacchi1,4 & Marcello costantini5*
temporal sensitivity to multisensory stimuli has been shown to be reduced in obesity. We sought 
to investigate the possible role of the pro-inflammatory state on such alteration, considering the 
effect of the expression of markers, such as leptin and IL6, which are notably high in obesity. The 
performance of 15 male individuals affected by obesity and 15 normal-weight males was compared 
using two audiovisual temporal tasks, namely simultaneity judgment and temporal order judgment. 
Analyses of serum levels of inflammatory markers of leptin and IL6, and of neurotrophic factors of 
BDNF and S100SB were quantified. At the behavioral level we confirmed previous evidence showing 
poorer temporal sensitivity in obesity compared to normal-weight participants. furthermore, leptin, 
that is a cytokine overexpressed in obesity, represented the best predictor of behavioral differences 
between groups in both tasks. the hypothesis we put forward is that the immune system, rather than 
overall cerebral dysfunction, might contribute to explain the altered temporal sensitivity in obesity. 
The present finding is discussed within the context of the role of cytokines on the brain mechanisms 
supporting temporal sensitivity.
The brain mechanism through which two or more different sensory input, when occur at the same time and place, 
are coordinate together to create an unified and coherent internal representation of the world, is known as mul-
tisensory integration1. It has a substantial survival value for humans: the construction of a coherent multimodal 
representation of the external world allows humans to take advantage of the redundancies and complementarities 
provided by multiple sensory modalities2. Thus, considering the large impact of this process on our perception, 
it is not surprising to observe a growing interest in studying multisensory integration, and under what circum-
stances this process takes place or defects. Indeed, multisensory integration difficulties has been recognized in 
several clinical conditions3–5; for example, our group recently provided evidence about aberrant temporal multi-
sensory process in obesity6. Specifically, the behavioral measure of the audiovisual sensory integration, that it the 
temporal binding window, (i.e. “the epoch of time within which stimuli from different modalities is likely to be inte-
grated and perceptually bound” according to the definition provided by Wallace and Stevenson (2014)7, resulted 
to be markedly different in the participants affected by obesity as compared to healthy-weight controls; our result 
mirrored what found previously by Wan and colleagues (2014)8 about the integration of audio-vibrotactile sen-
sory input in overweight individuals.
A growing body of evidence suggests that the correct functioning of cerebral mechanisms, such as the syn-
chronized network oscillations9 (i.e. the rhythmic or repetitive electrical activity generated spontaneously and in 
response to stimuli by neural tissue in the central nervous system; it is one of the neural mechanisms implicated 
in multisensory integration process10–13), is related to the immune systems14, which act on the central nervous sys-
tem through chemical messengers15. In fact, as neural cells have receptors for cytokines, immune cells have recep-
tors for various neurotransmitters16 involved in brain activity14. For example, the well-known γ-aminobutyric 
acid (GABA), that is the principal inhibitory neurotransmitter in the central nervous system17, is essential for 
the efficient brain functioning, mediating neuronal activity, information processing and plasticity, and the 
synchronized network oscillations14. Glutamate18 and GABA19 were found to predict individual differences in 
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multisensory processing in healthy individuals: these components have inhibitory and exhibitory neuromod-
ulatory effects, regulating the brain’s response to sensory perception20. Interestingly, as suggested by multiple 
research in animals and humans, as well as in pathological and clinical conditions, both glutamate21 and GABA22 
are strictly related to inflammation: they can be considered as immunomodulators.
As in our knowledge, there is very few recent experimental evidence on the relationship between temporal 
sensitivity and inflammation. Focusing on obesity, as previously stated, our recent study6 and Wan and colleagues 
(2014)8’s work provided evidence about aberrant temporal multisensory process in this clinical condition. On 
the other hand, few research showed a correlation between resting state network dynamics and obesity23, and 
specifically an increased resting-state functional connectivity in severe obese adolescents24. How might these 
two different experimental evidences - the first one about an alteration of multisensory integration, the sec-
ondabout an alteration of cerebral activity in obesity be jointed? What might be the link between the functional 
cognitive process (i.e. multisensory integration) and cerebral activity? The turning point might be to look at obe-
sity as not just a clinical condition caused by the accumulation of fat, but as a more complex condition in which 
metabolic dysfunction affects central nervous system. Specifically, it is now, even though not fully25 established, 
that obesity is associated with chronic low-grade systemic inflammation26,27; indeed the adipose tissue secretes 
a range of bioactive peptides and proteins28, included pro-inflammatory cytokines, with knock-on effects on 
other complex metabolic processes. Cytokines are a type of regulators of host responses to infection, immune 
responses, inflammation, and trauma29. When the cytokines actions result in a worsening of the disease, they 
are defined as pro-inflammatory; when they are overexpressed, as in in obesity28, they define a state of chronic 
systemic inflammation, meaning a prolonged condition in which the entire body is active to react to an illness. 
One the most studied product of the adipose tissue is leptin: it mediates the relationship between environment 
(intended as availability of nutrients), metabolism, and immune responses30. Another known product of the fat 
is the interleukin 6 (IL-6); the expression of this cytokine increases with adiposity31 with an important role in 
the expression of the other cytokines32. Interestingly, even though cytokines are produced at the level of adipose 
tissue (i.e. a peripheral inflammation), their negative consequences in obesity can be observed far away from the 
production site (i.e. systemic inflammation), influencing behavior as well as brain development and functions33,34. 
Brain is, indeed, a key target of the chronic low-grade inflammation, which is a risk factor for neuroinflammation 
and anatomical alterations25,35–38. The mechanisms according to inflammatory state might alter anatomically and 
functionally brain activity is not clear yet (see Miller and Spencer (2014)25, for a review). However, the existing 
relationship between and brain functioning, and the evidence showing altered brain functioning in obesity, pose 
the question whether inflammation might represent a link between obesity and altered brain mechanisms25, such 
as temporal sensitivity to multisensory stimuli.
Moreover, factors that are generally considered as indices of cerebral plasticity are found to be altered in 
obesity, in absence of neurological disease: this is the case for brain-derived neurotrophic factor (BDNF)39,40 and 
S100 calcium binding protein B (S100B)41,42. In details, BDNF plays a prominent role in the survival, growth, and 
maintenance of neurons during development43,44 in the adult age45. S100B, that is a member of the S100 protein 
family, is commonly used as a parameter of glial activation and/or death in different disorders of the central nerv-
ous system; since its role in normal cerebral development and recovery after injury, it was suggest to be a potential 
neurobiochemical marker of neurological disorders46.
Thus, given the tight link between the brain and the immune system15, we tested the hypothesis that inflamma-
tory state in obesity might be related to poorer temporal sensitivity6. In particular, we address the question as to 
whether circulating levels of pro-inflammatory markers, such as leptin and IL-6, or markers of cerebral plasticity, 
such as BDND and S100B, are related to the temporal sensitivity in obesity, through a cross-sectional study. To 
this aim, the neurocognitive behavior of a sample of otherwise healthy obese men was tested by two experimental 
tasks assessing temporal sensitivity to multisensory stimuli6 compared to that obtained in a sample of control 
individuals with normal weight.
Blood levels of leptin, IL-6, BDNF and S100B were measured at the time of the testing in order to inves-
tigate the potential association with the pro-inflammatory pattern and its relation with neurotrophins. 
Pro-inflammatory cytokines production increases in response to acute psychological stress in humans47,48, sug-
gesting a relationship between stress and immune functions49,50. Since this relationship appears to be critical in 
obesity51–53, we also measured the level of cortisol in our population sample.
Results
Demographic and clinical data.  The participants with obesity and the healthy-weight participants were 
comparable in terms of Age (t(28) = 1.26; p = 0.21; d = 0.61; 95% CI [2; 8.4]) and years of Education (t(28) = 1.94; 
p = 0.062; d = 0.63; 95% CI [0.14; 5.34]). Data are reported in Table 1. As expected, participants affected by obe-
sity reported a significantly higher BMI than normal-weight participants (t(28) = 18.68; p < 0.001; d = 6.83; 95% 
CI [18.21; 22.69]); specifically for participants with obesity the mean value was higher than 44, suggesting that 
this condition can be classified as “morbidly obese stage III”54. No differences were observed when comparing 
Beck Depression Inventory55,56 scores between the two groups (t(28) = 1.88; p = 0.07; d = 0.69; 95% CI [0.21; 
5.28]). Moreover, both groups reported the same level of daytime sleepiness, as suggested by the score at the 
Epworth Sleepiness Scale57 (t(28) = 1.48; p = 0.14; d = 0.54; 95% CI [0.83; 5.23]).
Serum markers. Means and standard deviations of the serum marker levels are reported in Table 1. A sig-
nificant difference emerged between groups in the serum levels of leptin (Levene’s test F = 27.82; p < 0.001; t 
(14.24) = 7.036; p < 0.001: d = 2.56; 95% CI [27.72; 51.98]), as well as IL6 (Levene’s test F = 12.17; p = 0.002; t 
(17.84) = 5.28; p < 0.001; d = 1.93; 95% CI [0.69; 1.61]) and BDNF (t(28) = 7.036; p = 0.003; d = 1.2; 95% CI [1.5; 
6.45]). Instead, no differences were found for S100B (Levene’s test F = 4.59; p = 0.041; t(25.19) = 0.57; p = 0.57; 
95% CI [8.17; 14.54]) and cortisol (t(27) = 1.03; p = 0.3; 95% CI [1.51; 4.6]).
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Experimental tasks. Regarding the SJ, we evaluated the goodness of fit of our mathematical model: consid-
ering the data relative to the participants with obesity, the mean R2 was 0.86, while for the normal-weight group it 
was 0.93. The Temporal Binding Windows (TBW) values violated normality (Shapiro-Wilk test, p = 0.046), hence 
data were log-transformed to obtain a normal distribution. According to the independent sample t-test, par-
ticipants with obesity (Mean = 343 ms; SD = 84 ms) showed a wider TBW respect to the normal-weight group 
(Mean = 277 ms; SD = 80 ms) (t(28) = 2.16; p = 0.039; d = 0.8; 95% CI [− 126.67; −3.58]) (Fig. 1, left plot), con-
firming our previous results6.
According to the linear regression analysis, a significant regression was found [F(5, 23) = 3.23; p = 0.023] with 
an R2 of 0.41. A low level of multicollinearity was present (VIF = 2.5 for leptin, 2.17 for IL6, 1.1 for BDNF, 1.15 for 
S100B and 1.36 for cortisol). Leptin was the only significant predictor of the TBW [B = 2.097; p = 0.023] (Fig. 2); 
no other predictors were significant [IL6 B = −13.69; p = 0.58; BDNF B = −4.39; p = 0.25; S100B B = 1.12; 
p = 0.27; Cortisol B = −3; p = 0.46].
Regarding TOJ, we evaluated the goodness of fit: for the data relative to the participants with obesity, we 
observed a mean R2 of 0.84, while in the normal-weight group it was 0.96. The Just Noticeable Difference (JND) 
values violated normality (Shapiro-Wilk test, p < 0.001), hence again data were log-transformed to obtain a nor-
mal distribution. According to the independent sample t-test, the results showed larger JND in participants with 
obesity (Mean = 210 ms; SD = 99) compared to healthy-weight controls (Mean = 115 ms; SD = 42), t(28) = 3.76; 
p = 0.001; d = 1.24; 95% CI [−0.37; −0.11] (Fig. 1, right plot). This result is in line with our previous report23. 
According to the linear regression analysis, a significant regression equation was found [F(5, 23) = 8.34 p < 0.001] 
with an R2 of 0.64. Leptin [B = 3.29; p < 0.001] was the only significant predictor also for the JND (Fig. 3); no 
other predictors were significant [IL6 B = −32.77; p = 0.1; BDNF B = 0.15; p = 0.96; S100B B = 1.16; p = 0.15; 
Cortisol B = 0.14; p = 0.96].
Overall, we confirmed that individuals with obesity showed a wider TBW in SJ and a higher JND in TOJ 
respect to the healthy-weight controls, suggesting an alteration in the process of integration of multiple sensory 
stimuli. The behavior was predicted by the level of leptin measured in the serum in both tasks, as indicated by 
results in the linear regression analyses.
Participants with 
obesity
Healthy-weight 
participants p-value
Age 34 (6) 30 (7) 0.21
Education 13 (4) 15 (2) 0.06
BMI 44.24 (3.7) 23.7 (2) <0.001*
BDI score 6.4 (4.2) 3.86 (3.06) 0.07
ESS score 6.6 (4.98) 4.4 (2.84) 0.14
Leptin 42.77 (21.84) 2.92 (2.04) <0.001*
IL6 1.64 (0.79) 0.49 (0.29) <0.001*
BDNF 17.82 (3.56) 13.83 (3.02) 0.003*
S100B 23.24 (12.39) 20.05 (17.53) 0.57
Cortisol 12.84 (4.33) 14.39 (3.63) 0.3
Table 1. Demographic and clinical data for the participants with obesity and the normal-weight participants. 
Means and standard deviations (in brackets) are reported. Age in years is reported; Education is reported as 
years of school attended; BMI = body mass index express in units of kg/m2. BDI stands for the Beck Depression 
Inventory; ESS for the Epworth Sleepiness Scale. *Identifies a significant difference between the two groups.
Figure 1. Left plot: Group mean TBW defined using the Simultaneity Judgment (SJ) task. Right plot: Group 
mean JND values defined using the Temporal Order Judgment (TOJ) task. Red curves represent obese 
participants, black curves represent healthy-weight controls. Symbols represent the raw, unfitted data.
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Discussion
In the present work, we searched for an alteration of temporal sensitivity to multisensory stimuli in individuals 
affected by obesity. Moreover, we extend our investigation to test a potential relationship linking neurocognitive 
behavior to blood-based markers for pro-inflammatory state (leptin and IL6) and to those neurotrophic factors 
considered sensitive biochemical markers of cerebral injury (BDNF and S100B).
Focusing on the behavioral task, we found that temporal sensitivity to multisensory stimuli was markedly 
wider in participants affected by obesity compared to healthy-weight participants. This result is in line with our 
previous results6 and also it mirrors what reported by Wan and colleagues (2000)8. Furthermore, in the present 
study, we showed that the difficulties of individuals affected by obesity seem to be related to higher levels of 
pro-inflammatory markers, instead of indexes of cerebral lesion, when measured in the blood. More specifically, 
according to the regression analyses, leptin, but not IL-6, was the best predictor for individuals’ performance in 
both tasks. However, it can be observed that both peripheral leptin and IL-6 are known as pro-inflammatory 
cytokines and they are able to cross the blood brain barrier and affect brain function58. Our results appeared 
to be in line with previous works suggesting the role of leptin in brain activity48,59–61. Moreover, GABA, that is 
involved in the long-lasting brain changes (as we have underlined in the Introduction), is also implicated not 
only in the regulation of food intake62, appetite63 and feeding behavior64, that are really crucial in obesity, but also 
in leptin expression65,66. This link might be a key research for the future in which the involvement of GABA in 
the long-lasting brain changes that occur in obesity. If leptin was found to be a significant predictor for individ-
uals’ performance in both experimental tasks, a negative result emerged about IL-6, that represented the other 
index of inflammatory state adopted in the present study. Research has shown that also IL-6 plays a role in brain 
Figure 2. The relationship between the TBW (x-axys) defined using the Simultaneity Judgment (SJ) Task and 
the level of leptin (y axys) split for the two groups (filled circle: participants with obesity; empty circle: normal-
weight participants).
Figure 3. The relationship between the JND (x-axys) using the Temporal Order Judgment (TOJ) task. and the 
level of leptin (y axys) split for the two groups (filled circle: participants with obesity; empty circle: normal-
weight participants).
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functioning67–71 and in this sense it might be expected a relationship with the participants’ behavior in experimen-
tal tasks. However, it should be considered that even though IL-6 is a critical factor in mediating obesity-related 
consequences, the question related to which of the several mechanisms through which the adipose tissue-derived 
IL-6 may affect metabolism is still debated72.
The two markers of cerebral plasticity (BDNF and S100B) were not significant predictors of the behavior in 
our participants, corroborating our hypothesis about the relationship between inflammatory state and poorer 
temporal sensitivity in obesity. However, while the two groups shown different level of serum concentration of 
BDNF, such a difference did not emerge about S100B. The prominent role of the neurotrophin BDNF in survival, 
growth, and maintenance of neurons during development43,44 also in pathological conditions (see Habtemariam, 
201873 for a recent review) is well established, while it still need to be completely clarified its role in obesity; indeed 
we registered higher level of BNDF in our sample of individuals affected by obesity, respect to healthy-weight 
controls, and this result is in line with previous studies in the field74,75; however, it should be noted that reduced 
level of circulating BDNF levels in individuals affected by obesity respect to controls76,77 as well as no differences 
between the two groups78  were also reported. Nevertheless, there is an overall consensus in suggesting the pos-
sible critical role of BDNF in obesity; altered BDNF production was found to be associated with weight loss and 
food behavior in experimental animal models79–81 and in humans82. Interestingly, BDNF is also associated with 
energy homeostasis83; thus changes in circulating BDNF in obesity are likely secondary to the altered energy 
balance occurring in this condition84.
As mentioned earlier, the two groups did not differ in the serum level of S100B. This is as unexpected result, 
and possibly due to the magnitude of interindividual variation in S100B values observed especially among 
normal-weight participants. S100B it is produced primarily by brain astrocytes and its elevated levels are gen-
erally linked to glial damage or dysfunction in blood-brain barrier85,86, as usually observed in different cerebral 
diseases85–87. Also high concentration of S100B is observed in the serum of obese patients and it is significantly 
correlated with higher level of body mass index88, even though Pham and colleagues (2010)89 reported opposite 
results, since they did not observed statistically significant relationship between BMI and S100B levels in their 
large samples of studied individuals. Thus, they concluded that “an increase in fat mass might not in isolation be a 
major contributor to elevated S100B levels”89, suggesting the possible contribution of other obesity-related diseases 
in the expression of the protein. According to Aleksovska and colleagues (2014)87, S100B is more than a marker 
of brain damage; rather, its higher level in the brain would make the individuals more exposed to higher risk of 
developing psychiatric disorders in a stressful environment. Further research about S100B and its meaning in 
terms of cerebral wellbeing are necessary.
Finally, the two groups did not differ in the serum level of cortisol, that is a marker of acute psychological 
stress47,48. Individual variations in endocrine response to stress is reported to impact the level of expression of 
pro-inflammatory cytokines, as well as both high and low cortisol stress responsiveness has potentially adverse 
effects in maintain mental wellbeing90. Thus the absence of statistically higher level of cortisol in the participants 
affected by obesity respect to the normal-weight group might related to the pro-inflammatory condition mediated 
by the immune system, instead of a spread, unspecific response to a stressful condition.
In conclusion, we suggest that aberrant performance of individuals affected by obesity in temporal tasks might 
be, at least in part, explained by the serum level of pro-inflammatory marker of leptin. Future studies should 
investigate what might be the physiological mechanism maintaining the observed effects: other possible immuno-
logical components91, measured not only at the peripheral level (i.e. in the blood) but also at a central level (i.e. in 
the brain), should be considered. Another interesting investigation might be to consider the temporal time-course 
of immune products in relation to behavior, and to adopt neurophysiological techniques allowing to measure 
directly the cerebral activity associated to the behavior. Moreover, considering the magnitude of interindividual 
variation in markers concentrations, in future the numbers of participants should be enlarged. Finally, in this 
work only male individuals were assessed. Sex hormones appear to influence the immune response in humans 
(see Bouman et al.92 for a review); in other words, females and males show different hormones with different effect 
on immune systems. Thus, in future, it would be interesting to replicate this study focusing on the females’ behav-
iour, taken carefully in account the specificity of the female immune system. Even though this study is not exhaus-
tive, it might shed the light of on a possible link between immune system, temporal sensitivity and brain activity93.
Methods
participants. Fifteen male individuals affected by obesity and fifteen male normal-weight individuals took 
part in the study. All participants were right-handed. Subjects volunteer to participate; they gave informed written 
consent, were free to withdraw at will and were naïve to the rationale of the experiment. The study was approved 
by the IRCCS Istituto Auxologico Italiano Ethics Committee. The study protocol conformed to the guidelines of 
the European Convention on Human Rights and Biomedicine concerning biomedical research. All participants 
with obesity were consecutively recruited at admission to our institution (IRCCS Istituto Auxologico Italiano, 
Ospedale San Giuseppe). All subjects were nonsmokers and free from gastrointestinal, cardiovascular, psychiat-
ric, or metabolic disorders or any concurrent medical condition not related to obesity. Moreover, no participant 
with diagnosis of Obstructive Obstructive Sleep Apnea syndrome (according to routinely clinical assessment) 
was included in the present study. We measured the level of daytime sleepiness through the Italian version94 of the 
Epworth Sleepiness Scale57; according to this scale, a score under the cut-off of 6 indicates no difficulty in daily 
level of alertness. All subjects underwent body measurements wearing light underwear, in fasting conditions after 
voiding. Weight and height were measured to the nearest 0.1 kg and 0.1 cm, respectively, using standard methods. 
BMI was expressed as body mass (kg)/height (m)2. Obesity was defined for any BMI over 30 kg/m2. We measured 
also the level of depressive symptoms through the Italian version56 of the Beck Depression Inventory55; a score 
under the cut-off of 9 indicates no pathological level of depressive symptoms. Demographic and clinical data for 
the participants with obesity and the normal-weight participants were reported in Table 1.
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Serum markers. Testing was performed at 08.00 a.m. in fasting conditions and after voiding. About partici-
pants with obesity, the testing was performed within one week after admission while patients were fed a balanced 
diet (30% lipids, 50% carbohydrates, and 20% proteins).
Blood samples were drawn under fasting conditions and were separated by centrifugation after clotting, pro-
cessed for routine measurement or aliquoted and stored at −80 °C until required.
Serum leptin concentrations were quantified using a commercially available ELISA kit (Mediagnost GmbH, 
Reutlingen, Germany) with sensitivity of 0.2134 ng/mL and overall inter- and intra-assay coefficients of variation 
(CV) of 6.8–8.3% and 5.5–6.9% respectively.
Serum IL-6 levels were measured using a Human IL-6 Quantikine HS ELISA (R&D systems, Minneapolis, 
MN, USA). Assay sensitivities for IL-6 is estimated at 0.039 pg/ml. Intra- and inter-assay precision CV for IL-6 
were estimated at less than 7.4%, and less than 9.6%, respectively.
Serum BDNF were measured using a Human BDNF Quantikine ELISA (R&D systems, Minneapolis, MN, 
USA). Assay sensitivities, or minimum detectable concentrations for BDNF is estimated at 20 pg/ml. Respective 
intra- and inter-assay precision CV for BDNF are estimated at less than 6.2% and less than 11.3%,respectively, as 
reported by the manufacturer.
Serum S-100B level were measured using a human S100B ELISA (Diametra, Spello, Italy) having a sensitivity 
of 35.27 pg/ml, inter- and intra-assay CV of less than 11.7% and 10.2% respectively.
Levels of serum cortisol was measured using Cobas 6000 (Roche Diagnostics, Indianapolis, IN, USA).
Experimental tasks. All stimuli were presented using OpenSesame 2.9.695. Visual stimuli consisted of a 
white ring circumscribing a visual fixation cross on a black background and were 1.8 cm in diameter or 1.7° of 
visual angle. They were presented at a distance of approximately 60 cm from the participants and lasted 30 ms. 
Auditory stimuli consisted of a 3.500 Hz pure tone. They were presented binaurally via noise-cancelling head-
phones and lasted 30 ms.
Participants performed the Simultaneity Judgment Task (SJ) and the Temporal Order Judgment Task (TOJ) 
in separate sessions. In both tasks, visual and auditory stimuli were delivered sequentially with one of the follow-
ing Stimulus Onset Asynchronies (SOAs): 0; ±50, ±100, ±150, ±200, ±250, ±300, ±350, ±400 for SJ and SOAs
: ±50, ±100, ±150, ±200, ±250, ±300, ±350, ±400 for TOJ. Negative SOAs indicate that the auditory stimulus 
is presented first (auditory leading trials), whereas positive SOAs indicate that the visual stimulus is presented 
first (visual leading trials). In the SJ task, participants reported whether the auditory and visual stimuli were pre-
sented at the same or different times. In the TOJ task, participants reported which stimulus came first. The inter-
trial interval (ITI) ranged between 1500 and 2500 ms. The presentation of the stimuli was pseudo-randomized. 
Participants performed two blocks for each task. In each block, each SOA was presented 16 times, for a total of 
288 trials per block in SJ and 256 trials per block in TOJ. Overall participants completed 576 trials for the SJ task 
and 512 trials for TOJ task. Tasks order was counterbalanced across participants.
During the experiment, participants were seated in a dimly lit room with their corporeal midline aligned with 
a fixation point located 60 cm from the plane of their eyes. They rested their right and left index fingers on two 
response buttons located on a table. Each hand was in its homonymous hemispace. Participants were instructed 
to fixate toward a fixation cross at all times. They provided their answers by pressing a response button with 
the right or the left index finger, with the button representation (synchronous/asynchronous or auditory-first/
visual-first) being balanced across blocks. In the Fig. 4, a graphical representation of the experiment is reported.
Statistical analyses. The differences between groups in serum marker levels were assessed using independ-
ent sample t-tests. The individual’s Temporal Binding Windows (TBW) in the SJ task, and the Just Noticeable 
Difference (JND) in the TOJ task (i.e. measures of temporal sensitivity) for each group were calculated using 
Figure 4. Graphical representation of stimuli presentation.
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standard procedures96,97. Specifically, to calculate the individual’s TBWs in the SJ task, we first computed the per-
centage of simultaneous responses across all SOAs for each participant. The observed distribution of responses 
was fitted to a Gaussian function using the fit function implemented in MATLAB (fit type: gauss1). The peak of 
this curve is referred to as the point of subjective simultaneity (PSS). It is assumed that, at this particular SOA, the 
information from the different modalities is perceived as being maximally simultaneous. Another measure that 
can be derived from this curve is its standard deviation. The standard deviation is reflected in the width of the 
curve and is taken as the TBW, because it represents the range of SOAs at which the brain treats the two sensory 
information as occurring simultaneously. For the TOJ task, data analysis was as follows: first we calculated a rate of 
visual-first responses with each SOA. Then, a single psychometric function was fitted to the response rates across 
all SOAs, using the glmfit function in MATLAB, so as to determine the just noticeable difference (JND) for each 
group. The JND was defined as half of the difference between the two x values for which the psychometric func-
tion had a y value of 25% and 75%. For both tasks, we report the goodness of fit through the adjusted R-square. 
Possible differences between the TBW and the JND between groups were tested using independent sample t-tests. 
A post hoc power analysis was conducted using the software package, GPower 3.0.198. For both groups, a sample 
size of 15 was used; moreover the alpha level used for this analysis was p < 0.05. The post hoc analyses revealed 
the statistical power for this study was 0.37 for detecting a medium effect size (d = 0.5), whereas it was of 0.68 for a 
large effect size d = 0.8. Finally, a linear regression was calculated to predict TWB and JND based on the all serum 
marker levels; the variance inflation factor (VIF) is reported as measure of multicollinearity.
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